HOME >> BIOLOGY >> NEWS
Targeted Genetics presents data on arthritis gene therapy

AAV delivery of gene encoding ENBREL shows promise in reducing inflammation in preclinical studies

Seattle, WA-June 5, 2000-Targeted Genetics Corporation (Nasdaq:TGEN) presented data from its gene therapy program for rheumatoid arthritis (RA) this weekend at the American Society of Gene Therapy Third Annual Meeting in Denver, Colorado. The Company is utilizing its adeno-associated virus (AAV) vector technology to deliver the DNA sequence encoding tumor necrosis factor receptor-immunoglobulin Fc fusion protein (TNFR:Fc) as a treatment for RA and other inflammatory diseases. Recombinant TNFR:Fc, ENBREL (etanercept), currently marketed for the treatment of several forms of RA, was developed by Immunex Corporation. Targeted Genetics obtained rights to the gene therapy applications of numerous genes and gene delivery technologies when it was spun out of Immunex in 1992.

Dr. Haim Burstein, Senior Scientist in the Department of Research at Targeted Genetics, presented the data in an abstract titled "Treatment of Experimental Arthritis Using Recombinant AAV-TNFR:Fc Vector Gene Therapy." The studies were conducted in collaboration with Dr. Sharon M. Wahl at the National Institute of Dental and Craniofacial Research, an institute of the National Institutes of Health. In these studies, recombinant AAV vectors containing the TNFR:Fc fusion genes were evaluated in an experimental rat model of arthritis. A single intra-articular (joint) administration of AAV-rTNFR:Fc into both rear ankle joints of arthritic rats resulted in a significant reduction of ankle and hind paw swelling as measured by arthritis index scores. A single intramuscular administration produced a similar effect. Bioactive rat TNFR:Fc protein was readily detectable in the serum of treated rats 33 days after intramuscular administration of AAV-rTNFR:Fc compared to control animals.

Injection of AAV-rTNFR:Fc into a single joint led to a reduction in hind paw swelling in the c
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
4-Jun-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2018)... (PRWEB) , ... August 07, 2018 , ... CallTower ... today their new CT Cloud Voice and SIP solutions. CT Cloud solutions are ... secure, quality voice solution that is far superior to traditional PBX systems, at a ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder ... winning recipients of the 2018 IAC Awards at the 23rd World Congress on Heart ... also named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, ...
(Date:8/1/2018)... , ... August 01, 2018 , ... Visikol CEO Dr. ... services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 ... developing its suite of digital pathology tools, whole mount imaging ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ... was developed and is continually updated by a talented scientific team that includes ... service provides: , 1. Information on the medical impact of a patient’s ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... ... 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory. ... controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based ... combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for ... was reported:, Over 70% decrease in Interleukin (IL-1ß) ...
Breaking Biology Technology:
Cached News: